AbbVie Inc. (ABBV – Analyst Report) reported third quarter 2015 earnings of $1.13 per share, up 27% from the year-ago quarter and surpassing the Zacks Consensus Estimate of $1.07.

Abbvie Inc. (ABBV – Analyst Report) – Earnings Surprise | FindTheCompany

Revenues increased 18.4% to $5.944 billion in the third quarter of 2015, surpassing the Zacks Consensus Estimate of $5.894 billion.

The Quarter in Details

Key drug Humira recorded growth of 12.1% with revenues coming in at $3.6 billion. U.S. sales increased 30.4% ($2.3 billion) driven by growth across all three major market categories: rheumatology, dermatology and gastroenterology. Ex-U.S. sales declined 8.9% to $1.4 billion, impacted by negative currency movement (16%). Growing awareness, favorable clinical data, additional indications and expansion into new markets should help the product to continue contributing significantly to the top-line.

Other products that performed well include Lupron (up 2.4% to $201 million), and Creon (up 8.3% to $161 million). HCV product Viekira recorded sales of $469 million, up from $385 million in the second quarter of 2015.

AbbVie recorded Imbruvica U.S. sales of $267 million and $37 million of international profit sharing.

Meanwhile, products like AndroGel, Synagis, Synthroid and Kaletra (HIV) recorded a decline in revenues. While AndroGel 1% is facing generic competition, Kaletra was most likely impacted by negative market trends.

Ups 2015 View

AbbVie raised its earnings guidance to $4.26 – $4.28 per share (guidance provided with second quarter results: $4.10 – $4.30 per share). The Zacks Consensus Estimate of $4.25 is below the guidance range.

2016 Guidance In-Line With Expectations

The company also provided its earnings outlook for 2016 – AbbVie expects earnings of $4.90 – $5.10 per share in 2016. The Zacks Consensus Estimate of $4.97 is within this guidance range.

AbbVie also announced a 12% increase in 2016 dividend.